Overall, our results suggest that drug resistance in GIST cell lines to KIT inhibitors could be overcome through combined KIT/MAPK or KIT/PI3K/MAPK pathway inhibition. The gene discussed is PIK3CA; the disease is gastrointestinal stromal tumor.